NAS:HALO (USA)
Business Description
Halozyme Therapeutics Inc
NAICS : 325414
SIC : 2836
11388 Sorrento Valley Road, San Diego, CA, USA, 92121
Compare
Compare
Traded in other countries / regions
RV7.Germany
•
HALO.Mexico
•
0J2O.UK
•
HALO.USA
Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 4.25 | |||||
Debt-to-EBITDA | 4.85 | |||||
Interest Coverage | 27.89 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.38 | |||||
Beneish M-Score | 14.9 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 41.9 | |||||
3-Year Book Growth Rate | -5.9 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 11.81 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.01 | |||||
9-Day RSI | 34.92 | |||||
14-Day RSI | 38.36 | |||||
6-1 Month Momentum % | 48.88 | |||||
12-1 Month Momentum % | 20.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.72 | |||||
Quick Ratio | 2.23 | |||||
Cash Ratio | 1.05 | |||||
Days Inventory | 254.42 | |||||
Days Sales Outstanding | 94.64 | |||||
Days Payable | 18.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.7 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.53 | |||||
Operating Margin % | 49.61 | |||||
Net Margin % | 75.11 | |||||
ROE % | 158.95 | |||||
ROA % | 29.25 | |||||
ROIC % | 68.67 | |||||
ROC (Joel Greenblatt) % | 119.37 | |||||
ROCE % | 21.59 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 16.89 | |||||
PE Ratio without NRI | 16.89 | |||||
Shiller PE Ratio | 697.04 | |||||
Price-to-Owner-Earnings | 14.49 | |||||
PS Ratio | 12.58 | |||||
PB Ratio | 20.07 | |||||
Price-to-Free-Cash-Flow | 21.27 | |||||
Price-to-Operating-Cash-Flow | 21.13 | |||||
EV-to-EBIT | 28.62 | |||||
EV-to-EBITDA | 26.96 | |||||
EV-to-Revenue | 14.2 | |||||
EV-to-Forward-Revenue | 11.82 | |||||
EV-to-FCF | 24.19 | |||||
Price-to-Projected-FCF | 5.34 | |||||
Price-to-Median-PS-Value | 0.84 | |||||
Earnings Yield (Greenblatt) % | 3.5 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:HALO
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 487.477 | ||
EPS (TTM) ($) | 2.53 | ||
Beta | 1.19 | ||
Volatility % | 39.34 | ||
14-Day RSI | 38.36 | ||
14-Day ATR ($) | 1.962842 | ||
20-Day SMA ($) | 46.8305 | ||
12-1 Month Momentum % | 20.73 | ||
52-Week Range ($) | 31.36 - 52.98 | ||
Shares Outstanding (Mil) | 137.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Halozyme Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |